- Conditions
- Adiposity, Blood Pressure, Insulin Sensitivity, Lipoproteins, Weight Gain
- Interventions
- Calorie free flavored water beverage, Stevia sweetened beverages, Sucrose sweetened beverage
- Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–234
of 234
matching trials from the local directory fallback.
- Conditions
- Acceptability, Anthropometrics, Body Composition, College Student, Dietary Guidelines for Americans, Dietary Quality, Feasibility Studies, Gut Microbiome, Herbs and Spices, Inflammation Biomarkers, Lipid Profiles
- Interventions
- Herbs and Spices Nutrition Education Program
- Behavioral
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Antiphospholipid Syndrome (APS)
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypertension and Hyperlipidemia
- Interventions
- HTN and Medication Adherence
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Apolipoprotein L1, Chronic Kidney Diseases, Kidney Transplantation
- Interventions
- APOL1 genetic testing, Components of Genetic Counseling, EHR integration
- Diagnostic Test · Behavioral · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois
- Conditions
- Cardiovascular Disease and Lipoprotein(a)
- Interventions
- Placebo, TQJ230
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 287
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
- Conditions
- Diabetes, Dyslipidemia, Emergency Medicine, Hyperglycemia, Hyperlipidemia, Hypertension, Metabolic Syndrome, Obesity &Amp; Overweight
- Interventions
- Composite intervention to address MetS
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Generalized Lipodystrophy
- Interventions
- mibavademab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Ann Arbor, Michigan
- Conditions
- Cardiovascular Diseases, Dyslipidemias, Hypertension, Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 648 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Fort Carson, Colorado • Hinesville, Georgia • Fort Campbell, Kentucky + 3 more
- Conditions
- Blood Pressure, Fasting Glucose, Lipid Profile
- Interventions
- Progressive Barbell Strength Training
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 15 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Bladder Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Cancer, Diabetes Mellitus, Endometrial Cancer, Hyperlipidemia (E.G., Hypercholesterolemia), Hypertension, Prostate Cancer (Adenocarcinoma)
- Interventions
- PC2: Primary Care Connect
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Cardiometabolic Conditions, Dyslipidemia, Hypertension (HTN), Overweight (BMI > 25), Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Weight Loss Trial
- Interventions
- PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
- Behavioral
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Honolulu, Hawaii
- Conditions
- Lipedema
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- MPS3, Sanfilippo Syndrome
- Interventions
- Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day
- Drug
- Lead sponsor
- Ozlem Goker-Alpan
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Lipid Metabolism
- Interventions
- Obicetrapib
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cleft Lip, Cleft Palate
- Interventions
- Static Images and Facial Videos
- Other
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 0 Months to 21 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina
- Conditions
- Cleft Lip and Palate
- Interventions
- Bupivacain, Epinephrine, Liposomal Bupivacaine
- Drug
- Lead sponsor
- Kerry O'Rourke
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois